SCHEMBL18874071

SCHEMBL18874071

Cn1nc(-c2ccc(O)nc2)c2c(N)ncnc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 16/20 0.65
PIK3CA P42336 16/20 0.65
PIK3CB P42338 16/20 0.65
PRKDC P78527 16/20 0.65
PIK3CG P48736 15/20 0.65
ABL1 P00519 14/20 0.65
EGFR P00533 14/20 0.65
SRC P12931 14/20 0.65
MTOR P42345 14/20 0.65
HCK P08631 13/20 0.65
EPHB4 P54760 13/20 0.65
KDR P35968 13/20 0.65
PI4KB Q9UBF8 6/20 0.65
NUDT14 O95848 1/20 0.58
NUDT5 Q9UKK9 1/20 0.58
AURKB Q96GD4 2/20 0.50
AURKA O14965 1/20 0.50
IKBKE Q14164 1/20 0.50
KDM4E B2RXH2 1/20 0.46
PLK4 O00444 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130419 0.85 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL23917419 0.84 PIK3CD (0.60) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL128512 0.84 PIK3CD (0.60) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL18868078 0.83 SRC (0.75) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL18874072 0.82 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL130502 0.81 PIK3CD (0.60) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL12366 0.81 NUDT14 (0.69) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL30782445 0.81 NUDT14 (0.69) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL130637 0.81 PIK3CD (0.81) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG
SCHEMBL13826003 0.80 SRC (0.68) PIK3CDPIK3CAPIK3CBPRKDCPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885PIK3CA 6/4885PIK3CB 3/4885
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 PIK3CD 5/4885PIK3CA 4/4885PIK3CB 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.